Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA

Agrawal, Shruti; Misra, Ramnath; Aggarwal, Amita

doi:10.1007/s10067-006-0275-5

Cited by 89 publications

(71 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies demonstrate the association of anti-CCP positivity with joint destruction in patients with established RA (15,16,17). In our study, joint erosions and deformities were not associated with anti-CCP positivity.…”

Section: Discussionsupporting

confidence: 49%

Romatoid Artritli Hastalarda Serum Anti-Cyclic Citrullinated Peptid Antikor Düzeyleri ve Hastalık Aktivitesi Arasındaki İlişki

...

2012

Tftr

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 49%

Romatoid Artritli Hastalarda Serum Anti-Cyclic Citrullinated Peptid Antikor Düzeyleri ve Hastalık Aktivitesi Arasındaki İlişki

...

2012

Tftr

View full text Add to dashboard Cite

“…Anti-CCP antibodies are highly specific markers of RA and are detected in 58 -82% of patients (9,10,17,18). In patients with RA, these autoantibodies are associated with greater inflammatory activity, poorer radiologic outcome, higher frequency of extraarticular manifestations, and poorer outcomes in early arthritis.…”

Section: Discussionmentioning

confidence: 99%

“…In patients with RA, these autoantibodies are associated with greater inflammatory activity, poorer radiologic outcome, higher frequency of extraarticular manifestations, and poorer outcomes in early arthritis. The anti-CCP response may also be involved in the pathogenesis of RA because of both the presence of antibodies directed against citrullinated proteins in the target tissue and the association between anti-CCP antibodies and severe RA (7,11,(17)(18)(19)(20)(21).…”

Section: Discussionmentioning

confidence: 99%

Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

López‐Longo

Oliver-Miñarro

Torre

et al. 2009

Arthritis & Rheumatism

160

View full text Add to dashboard Cite

Objective. Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular disease that may not always be related to the presence of traditional cardiovascular risk factors. The aim of this study was to determine if anti-cyclic citrullinated peptide (anti-CCP) antibodies are associated with cardiovascular disease in patients with RA. Methods. Anti-CCP antibodies were determined by enzyme-linked immunosorbent assay in the earliest serum sample available from 937 patients with a diagnosis of RA. We studied the relationship between anti-CCP antibodies with traditional cardiovascular risk factors and cardiovascular events. Results. We found positive anti-CCP antibodies (>25 units/ml) in 672 patients (71.7%). There was no association between the anti-CCP antibodies and cardiovascular risk factors such as smoking, hypertension, dyslipidemia, being overweight, or diabetes mellitus. However, patients who had positive anti-CCP antibodies experienced more frequent ischemic heart disease (6.5% versus 2.6%; odds ratio [OR] 2.58, 95% confidence interval [95% CI] 1.17-5.65) and had higher mortality rates (11.2% versus 6.8%; OR 1.72, 95% CI 1.01-2.91). Similar results were obtained when we considered anti-CCP titers 20-fold higher (>500 units/ml). Multivariable analysis showed that ischemic heart disease is independently associated with positive anti-CCP antibodies (OR 2.8, 95% CI 1.19 -6.56; P ‫؍‬ 0.009). Conclusion. Anti-CCP antibodies in patients with RA are independently associated with the development of ischemic heart disease.

show abstract

“…Presence of anti-CCPs before onset as well as in established RA is associated with more severe radiological damage [13] and thus disease severity [14]. In a pilot study on 33 patients, we could clearly demonstrate a significant decrease of anti-CCPs in AS patients after receiving LDRnHT.…”

Section: Discussionmentioning

confidence: 62%

Radon-therapy in ankylosing spondylitis reduces auto-antibody titers

Moder¹,

Hufnagl²,

Jakab³

et al. 2011

OJMIP

View full text Add to dashboard Cite

Combined low-dose radon/hyperthermia therapy has been reported to improve pain and mobility in patients with rheumatic disorders. The key feature of inflammatory rheumatic diseases is the induction of autoimmune processes via the production of autoantibodies. As reducing the autoantibody level through administration of biologicals is described to correlate with delay of disease progression, we investigated the impact of combined low-dose radon/ hyperthermia therapy on the serum levels of antibodies directed against cyclic citrullinated peptides in patients with ankylosing spondylitis. We found that levels of circulating anti-CCP antibodies is significantly reduced immediately after a 3 weeks of radon therapy regimen.

show abstract

Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA

Abstract: Anti-CCP antibodies are present in majority of patients with established RA including seronegative patients. Both anti-CCP and AKA, in addition to conventional marker like IgM RF, are associated with severe erosive disease.

Cited by 89 publications

References 19 publications

Romatoid Artritli Hastalarda Serum Anti-Cyclic Citrullinated Peptid Antikor Düzeyleri ve Hastalık Aktivitesi Arasındaki İlişki

Romatoid Artritli Hastalarda Serum Anti-Cyclic Citrullinated Peptid Antikor Düzeyleri ve Hastalık Aktivitesi Arasındaki İlişki

Association between anti–cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis

Radon-therapy in ankylosing spondylitis reduces auto-antibody titers

Contact Info

Product

Resources

About